4 Biotechs To Consider On The Sector’s Trump Turnaround

2016-11-13-14_46_51-morguefile-free-photographs-for-commercial-useAfter being weighted down this year by the prospect of a Hillary Clinton administration focused on curbing drug prices, biotechs have seen a recovery since the unexpected victory of Donald Trump, whose campaign rhetoric suggests that he will be friendlier towards the industry. With this reversal of fortunes for the biotech sector, it may be worth considering the four biotech stocks recommended in today’s article, which was written before Trump even pulled off his surprise upset over Clinton. To read about these four biotechs that the author believes have the potential for market-beating gains – including the developer of the first noninvasive test for colorectal cancer – CLICK HERE.